CompaniesArno Therapeutics

Arno Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (8)
View all

Total Trials

8

As Lead Sponsor

6

As Collaborator

2

Total Enrollment

326

By Phase

PHASE1/PHASE2: 2PHASE1: 4PHASE2: 2

By Status

UNKNOWN: 4COMPLETED: 4
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
Today
NCT00389480
NCT00956787
NCT00978523
NCT01124539
NCT01129193
NCT02052128
NCT02049190
Hover over trial bars to see details

Recent Trials

NCT02049190Lead Sponsor
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
PHASE1/PHASE2Unknown
75 participants
Started: Feb 28, 2014 · Completed: Dec 31, 2017
NCT02052128Lead Sponsor
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
PHASE1/PHASE2Unknown
60 participants
Started: Jan 31, 2014 · Completed: Apr 30, 2016
NCT01202370Collaborator
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
PHASE1Completed
3 participants
Started: Sep 30, 2010 · Completed: Jul 31, 2011
NCT01129193Collaborator
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
PHASE1Completed
44 participants
Started: May 4, 2010 · Completed: Jan 7, 2017
NCT01124539Lead Sponsor
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
PHASE2Unknown
58 participants
Started: Dec 31, 2009 · Completed: Feb 28, 2015
View all 8 trials →